In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Majority of organizations are looking to increase investments in public and hybrid cloud
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
This project is supported by the Irish Government through IDA Ireland
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
Subscribe To Our Newsletter & Stay Updated
